PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Clinical and Molecular Hepatology10.3350/cmh.2014.20.2.1772014202177No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patientsNae-Yun Heo, Young-Suk Lim, Woochang Lee, Minkyung Oh, Jiyun An, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Han Chu Lee, Yung Sang Lee, Dong Jin Suhhttp://synapse.koreamed.org/pdf/10.3350/cmh.2014.20.2.177, http://synapse.koreamed.org/DOIx.php?id=10.3350/cmh.2014.20.2.177, http://www.e-cmh.org/upload/pdf/cmh-20-177.pdf
The Korean Journal of Hepatology10.3350/kjhep.2008.14.4.4432008144443Treatment of chronic hepatitis C: Efficacy of initial treatment of peginterferon alpha-2a versus peginterferon alpha-2b plus ribavirin in naive chronic hepatitis C patientsYoun Jae Leehttp://synapse.koreamed.org/pdf/10.3350/kjhep.2008.14.4.443, http://synapse.koreamed.org/DOIx.php?id=10.3350/kjhep.2008.14.4.443, http://www.e-cmh.org/upload/pdf/27403304.pdf
The Korean Journal of Hepatology10.3350/kjhep.2008.14.1.46200814146Comparison of therapeutic results between combination therapy of peginterferon alpha-2a plus ribavirin and interferon alpha-2b plus ribavirin according to treatment duration in patients with chronic hepatitis CHeon Ju Lee, Jong Ryul Eun, Jae Won Choi, Kyung Ok Kim, Hee Jung Moonhttp://synapse.koreamed.org/pdf/10.3350/kjhep.2008.14.1.46, http://synapse.koreamed.org/DOIx.php?id=10.3350/kjhep.2008.14.1.46, http://www.e-cmh.org/upload/pdf/27402958.pdf
Journal of Viral Hepatitis10.1111/j.1365-2893.2007.00862.x200700070701233506001-???Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis CA. M. Di Bisceglie, R. H. Ghalib, F. M. Hamzeh, V. K. Rustgihttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2893.2007.00862.x, http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2893.2007.00862.x/fullpdf
Hepatology Research10.1111/j.1872-034x.2012.01013.x20124210958-965Factors responsible for the discrepancy betweenIL28Bpolymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patientsHiroaki Saito, Kiyoaki Ito, Masaya Sugiyama, Teppei Matsui, Yoshihiko Aoki, Masatoshi Imamura, Kazumoto Murata, Naohiko Masaki, Hideyuki Nomura, Hiroshi Adachi, Shuhei Hige, Nobuyuki Enomoto, Naoya Sakamoto, Masayuki Kurosaki, Masashi Mizokami, Sumio Watanabehttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1872-034X.2012.01013.x
Gastroenterology10.1016/s0016-5085(12)63708-120121425S-957Sa1055 IL28B Polymorphism is Associated With Liver Steatosis and Treatment Response to PEG-Interferon Plus Ribavirin Combination Therapy, but is Not Associated With Hepatocarcinogenesis in Patients With Chronic Hepatitis CHidemi Goto, Kazuhiko Hayashi, Yoshihiko Tachihttps://api.elsevier.com/content/article/PII:S0016508512637081?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0016508512637081?httpAccept=text/plain
Hepatology10.1053/jhep.2003.503642003383645-652Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis CG Davishttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1053%2Fjhep.2003.50364, https://onlinelibrary.wiley.com/doi/full/10.1053/jhep.2003.50364
Value in Health10.1016/j.jval.2012.03.7512012154A139PGI24 Cost Effectiveness of the Combination of Boceprevir Plus Peginterferon Alpha and Ribavirin Versus Peginterferon Alfa Plus Ribavirin in the Retreatment of Patients with Chronic Hepatitis C Virus Genotype I InfectionM. Fonseca, G. Tannus, E. Parisihttps://api.elsevier.com/content/article/PII:S1098301512008169?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1098301512008169?httpAccept=text/plain
Value in Health10.1016/j.jval.2012.08.7702012157A329PGI21 Cost Effectiveness of the Combination of Boceprevir Plus Peginterferon Alpha and Ribavirin Versus Telaprevir Plus Peginterferon Alfa and Ribavirin in the Retreatment of Patients With Chronic Hepatitis C Virus Genotype I InfectionM. Fonseca, V. Garran, G.T. Araujohttps://api.elsevier.com/content/article/PII:S1098301512024837?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1098301512024837?httpAccept=text/plain
Value in Health10.1016/j.jval.2012.03.7522012154A139PGI25 Cost Effectiveness of Boceprevir Plus Peginterferon Alpha and Ribavirin Versus Peginterferon Alfa Plus Ribavirin in the Treatment of Chronic Hepatitis C (CHC) in Previously Untreated Genotype I PatientsM. Fonseca, G. Tannus, E. Parisihttps://api.elsevier.com/content/article/PII:S1098301512008170?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1098301512008170?httpAccept=text/plain